Arrowhead Pharmaceuticals Bilan de santé
Santé financière contrôle des critères 3/6
Arrowhead Pharmaceuticals possède un total de capitaux propres de $339.0M et une dette totale de $336.0M, ce qui porte son ratio d'endettement à 99.1%. Son actif total et son passif total sont $883.8M et de $544.8M.
Informations clés
99.1%
Ratio d'endettement
US$336.03m
Dette
| Ratio de couverture des intérêts | n/a |
| Argent liquide | US$434.47m |
| Fonds propres | US$338.97m |
| Total du passif | US$544.79m |
| Total des actifs | US$883.76m |
Mises à jour récentes de la santé financière
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) A Risky Investment?
Oct 04
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?
May 21Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?
Sep 19We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn
Oct 24Recent updates
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) A Risky Investment?
Oct 04Arrowhead Pharmaceutical: Driving To Commercialization
Jul 26Estimating The Fair Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jun 12Arrowhead Pharmaceuticals: Hoping Something Sticks
May 27Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?
May 21Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point
May 17Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding
Apr 03Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)
Mar 30Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package
Mar 08Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Feb 19Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy
Jan 21Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now
Dec 25Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?
Sep 19Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up
Apr 17Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now
Mar 10A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jan 24We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn
Oct 24Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities
Sep 12Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming
Aug 23Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease
Aug 17Arrowhead Pharmaceuticals: An RNAi Name To Know
Jul 28Arrowhead Pharmaceuticals names internal officer as new COO
Jul 20Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs
Jul 05Analyse de la situation financière
Passif à court terme: Les actifs à court terme de ARWR ( $450.1M ) dépassent ses passifs à court terme ( $96.7M ).
Passif à long terme: Les actifs à court terme de ARWR ( $450.1M ) dépassent ses passifs à long terme ( $448.1M ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: ARWR dispose de plus de liquidités que de sa dette totale.
Réduire la dette: Le ratio d'endettement de ARWR est passé de 0% à 99.1% au cours des 5 dernières années.
Bilan
Analyse des pistes de trésorerie
Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.
Piste de trésorerie stable: ARWR dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.
Prévisions de trésorerie: ARWR dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 47 % chaque année